Published in Ann Oncol on June 01, 2004
A randomised multicentre phase II study with cisplatin/docetaxel vs oxaliplatin/docetaxel as first-line therapy in patients with advanced or metastatic non-small cell lung cancer. Br J Cancer (2013) 0.94
Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer. Br J Cancer (2005) 0.86
Paclitaxel plus oxaliplatin for recurrent or metastatic cervical cancer: a New York Cancer Consortium Study. Gynecol Oncol (2009) 0.85
Modulation of tumor radiation response with G3139, a bcl-2 antisense oligonucleotide. Invest New Drugs (2007) 0.79
Nedaplatin or oxaliplatin combined with paclitaxel and docetaxel as first-line treatment for patients with advanced non-small cell lung cancer. Med Sci Monit (2014) 0.77
Oxaliplatin-Based Doublets Versus Cisplatin or Carboplatin-Based Doublets in the First-Line Treatment of Advanced Nonsmall Cell Lung Cancer. Medicine (Baltimore) (2015) 0.75
Efficacy and safety of docetaxel plus oxaliplatin as a first-line chemotherapy in patients with advanced or metastatic non-small cell lung cancer. Thorac Cancer (2014) 0.75
Lung cancer. Lancet (2000) 3.93
Stable binding to E2F is not required for the retinoblastoma protein to activate transcription, promote differentiation, and suppress tumor cell growth. Genes Dev (1998) 3.01
UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J (2002) 2.77
A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. Ann Oncol (2002) 2.42
Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity. Proc Natl Acad Sci U S A (1996) 2.30
MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines. Biochem Biophys Res Commun (2008) 2.15
Expression of bcl-xL can confer a multidrug resistance phenotype. Blood (1995) 2.11
Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal cancer. Ann Oncol (2003) 2.09
Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. Ann Oncol (2014) 1.97
Quantitative imaging study of extent of surgical resection and prognosis of malignant astrocytomas. Neurosurgery (1997) 1.90
Two outbreaks of sternal wound infection due to organisms of the Mycobacterium fortuitum complex. J Infect Dis (1981) 1.76
Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res (1994) 1.72
A reappraisal of the results of stopping therapy in childhood leukemia. N Engl J Med (1979) 1.64
5-Fluorouracil cardiotoxicity: a critical review. Ann Oncol (1990) 1.64
Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors. J Clin Oncol (1999) 1.56
Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J Natl Cancer Inst (2001) 1.55
Functional organ preservation with definitive chemoradiotherapy for T4 laryngeal squamous cell carcinoma. Ann Oncol (2008) 1.52
Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann Oncol (2002) 1.51
Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. J Clin Oncol (2004) 1.51
The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial. Cancer Epidemiol Biomarkers Prev (2001) 1.50
DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. Cancer Res (2001) 1.45
Human papilloma virus and p53 in head and neck cancer: clinical correlates and survival. Clin Cancer Res (1996) 1.44
Survival with inoperable lung cancer: an integration of prognostic variables based on simple clinical criteria. Cancer (1977) 1.44
A novel enhancer in the immunoglobulin lambda locus is duplicated and functionally independent of NF kappa B. Genes Dev (1990) 1.43
Multimodality therapy in advanced paranasal sinus carcinoma: superior long-term results. Cancer J Sci Am (1999) 1.42
An immunoprotective molecule, the major secretory protein of Legionella pneumophila, is not a virulence factor in a guinea pig model of Legionnaires' disease. J Clin Invest (1990) 1.41
Concomitant chemoradiotherapy, neutron boost, and adjuvant chemotherapy for anaplastic astrocytoma and glioblastoma multiforme. Cancer Invest (1995) 1.39
Combination chemotherapy in germinal cell tumors. Cancer Treat Rev (1976) 1.38
Distribution and functional consequences of nucleotide polymorphisms in the 3'-untranslated region of the human Sep15 gene. Cancer Res (2001) 1.35
Increased expression of unmethylated CDKN2D by 5-aza-2'-deoxycytidine in human lung cancer cells. Oncogene (2001) 1.30
Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study. J Clin Oncol (2000) 1.28
Quality of life and performance in advanced head and neck cancer patients on concomitant chemoradiotherapy: a prospective examination. J Clin Oncol (1999) 1.27
How Do head and neck cancer patients prioritize treatment outcomes before initiating treatment? J Clin Oncol (2000) 1.26
Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus. Ann Oncol (2005) 1.25
Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels. Ann Oncol (2008) 1.25
An anomaly of neutrophil morphology with impaired function. N Engl J Med (1974) 1.23
A phase II study of 9-aminocamptothecin in advanced non-small-cell lung cancer. Ann Oncol (1998) 1.23
Intravenous hyperalimentation as an adjunct to cancer chemotherapy. Am J Surg (1975) 1.22
Mutations affecting donor preference during mating type interconversion in Saccharomyces cerevisiae. Genetics (1995) 1.19
Variation of proliferative activity in leukemic cell populations of patients with acute leukemia. J Clin Invest (1967) 1.19
Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer. J Clin Oncol (2001) 1.18
False-positive blood cultures. Association with nonsterile blood collection tubes. JAMA (1976) 1.18
Drug effect in acute leukemia. J Clin Invest (1969) 1.18
Sorting mesoscopic objects with periodic potential landscapes: optical fractionation. Phys Rev E Stat Nonlin Soft Matter Phys (2004) 1.17
Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung. Blood (1987) 1.16
Bcl-xL is phosphorylated in malignant cells following microtubule disruption. Cancer Res (1998) 1.15
Sex-associated differences in presentation and survival in patients with lung cancer. J Clin Oncol (1990) 1.15
Control of influenza in the hospital. Ann Intern Med (1977) 1.14
The N-terminal domain of c-Myc associates with alpha-tubulin and microtubules in vivo and in vitro. Mol Cell Biol (1995) 1.14
Global methylation profiling of lung cancer identifies novel methylated genes. Neoplasia (2001) 1.14
Aneuploidy and percentage of S-phase cells determined by flow cytometry correlate with cell phenotype in childhood acute leukemia. Blood (1982) 1.13
Signal transduction pathways that regulate cell survival and cell death. Oncogene (1998) 1.13
Combined modality therapy of head and neck cancer. Semin Oncol (1994) 1.12
RB protein status and clinical correlation from 171 cell lines representing lung cancer, extrapulmonary small cell carcinoma, and mesothelioma. Oncogene (1994) 1.12
Partial inactivation of the RB product in a family with incomplete penetrance of familial retinoblastoma and benign retinal tumors. Oncogene (1994) 1.12
Phase I study of docetaxel with concomitant thoracic radiation therapy. J Clin Oncol (1998) 1.12
Variability in organ-specific EGFR mutational spectra in tumour epithelium and stroma may be the biological basis for differential responses to tyrosine kinase inhibitors. Br J Cancer (2005) 1.11
Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer. J Natl Cancer Inst (1997) 1.07
The current status of the treatment of childhood acute lymphoblastic leukemia. Cancer Treat Rev (1976) 1.07
Rearrangement of immunoglobulin heavy chain genes in T cell acute lymphoblastic leukemia. Blood (1985) 1.06
Characteristics of cell proliferation in four patients with untreated acute leukemia. Blood (1966) 1.06
Bcl-xL and Bcl-2 expression in squamous cell carcinoma of the head and neck. Cancer (1999) 1.04
Sequential therapy of acute leukemia in childhood. J Pediatr (1967) 1.04
Immunohistochemical analysis of the p16INK4 cyclin-dependent kinase inhibitor in malignant mesothelioma. J Natl Cancer Inst (1995) 1.04
New directions in the treatment of acute lymphoblastic leukemia in children. N Engl J Med (1986) 1.04
Large-dose bleomycin therapy and pulmonary toxicity. A possible role of prior radiotherapy. JAMA (1976) 1.04
Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. J Clin Oncol (1997) 1.03
The role of cervical lymphadenectomy after aggressive concomitant chemoradiotherapy: the feasibility of selective neck dissection. Arch Otolaryngol Head Neck Surg (2000) 1.03
Phase I study of 5-aza-2'-deoxycytidine in combination with valproic acid in non-small-cell lung cancer. Cancer Chemother Pharmacol (2012) 1.03
Combination chemotherapy and radiation therapy for small cell carcinoma. JAMA (1977) 1.02
Apoptosis is associated with cleavage of a 5 kDa fragment from RB which mimics dephosphorylation and modulates E2F binding. Oncogene (1997) 1.02
Swallowing function in patients with head and neck cancer prior to treatment. Arch Otolaryngol Head Neck Surg (2000) 1.02
Oral cavity tumors in younger patients show a poor prognosis and do not contain viral RNA. Oral Oncol (2013) 1.01
Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes. Bone Marrow Transplant (2005) 1.00
Phase II study of flavopiridol in patients with advanced colorectal cancer. Ann Oncol (2003) 0.99
Inhibition of immunoglobulin gene rearrangement by the expression of a lambda 2 transgene. J Exp Med (1989) 0.99
Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea. Clin Cancer Res (2000) 0.98
Functional analysis at the Cys706 residue of the retinoblastoma protein. J Biol Chem (1992) 0.98
Chemotherapy of metastatic non-small cell bronchogenic carcinoma. Semin Oncol (1983) 0.97
Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors. Ann Oncol (1998) 0.97
Cocaine-induced platelet defects. Stroke (1993) 0.96
Differential specificity for binding of retinoblastoma binding protein 2 to RB, p107, and TATA-binding protein. Mol Cell Biol (1994) 0.96
Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck. J Clin Oncol (1998) 0.95
Concordance for drug-induced aplastic anemia in identical twins. N Engl J Med (1969) 0.95
A Bcl-xL transgene promotes malignant conversion of chemically initiated skin papillomas. Cancer Res (1998) 0.95
Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors. J Clin Oncol (1999) 0.95